Skip to main content
Premium Trial:

Request an Annual Quote

Mark Gardner

OmniSeq has appointed Mark Gardner as its CEO and as a member of its board of directors. Gardner is currently vice president and general manager for Thermo Fisher Scientific's next generation clinical sequencing business. He will transition to his new role at OmniSeq in April. Prior to his work at Thermo Fisher, Gardner held senior management positions at McKinsey, GE Medical Systems, Invitrogen, and Life Technologies.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.